Details of the Drug

General Information of Drug (ID: DMG1DTE)

Drug Name
Penfluridol
Synonyms
PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
ATC Code
N05AG03: Penfluridol
N05AG: Diphenylbutylpiperidine derivatives
N05A: ANTIPSYCHOTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 524
Logarithm of the Partition Coefficient (xlogp) 7.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
Chemical Identifiers
Formula
C28H27ClF5NO
IUPAC Name
1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
Canonical SMILES
C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
InChI
InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
InChIKey
MDLAAYDRRZXJIF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
33630
ChEBI ID
CHEBI:92278
CAS Number
26864-56-2
UNII
25TLU22Q8H
DrugBank ID
DB13791
TTD ID
D0CQ0Z

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent 6-phosphofructokinase, liver type (PFKL) OTVHGAT7 PFKAL_HUMAN Gene/Protein Processing [3]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Gene/Protein Processing [3]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [3]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Post-Translational Modifications [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 1.7671 3.3277 1.7656 69.1814
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LN-229 CTRP1 1.695 2.5085 1.695 70.677
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP1 1.8886 3.3191 1.8878 67.647
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NU-DUL-1 CTRP1 1.0115 4.5883 0.9122 72.8377
SU-DHL-5 CTRP1 1.3289 2.368 1.3289 75.739
THP-1 CTRP1 1.3564 3.7038 1.3413 72.8445
OCI-AML-3 CTRP1 1.539 2.4827 1.539 72.8524
GDM-1 CTRP1 1.5442 2.8027 1.5441 72.5624
PL21 CTRP1 1.7321 2.994 1.7319 69.9563
NOMO-1 CTRP1 1.8165 3.0928 1.8162 68.7704
WSU-DLCL2 CTRP1 1.82 2.5308 1.82 68.9065
RPMI-8226 CTRP1 2.1554 2.9654 2.1554 64.1153
EJM CTRP1 2.2509 3.5443 2.2503 62.6616
SU-DHL-4 CTRP1 2.5439 4.6189 2.5196 58.1345
SKM-1 CTRP1 2.6538 3.6475 2.6537 56.9934
U-937 CTRP1 2.9032 3.5633 2.9032 53.4385
MOLM-16 CTRP1 3.0245 4.3021 3.0222 51.6975
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CW-2 CTRP1 1.1081 2.421 1.108 78.3775
SNU-C5 CTRP1 1.1883 2.1751 1.1883 77.7344
SNU-175 CTRP1 1.2751 2.8925 1.2741 75.616
SW620 CTRP1 1.3011 2.2744 1.3011 76.1771
SW480 CTRP1 1.3177 2.3826 1.3176 75.8735
SNU-81 CTRP1 1.3183 2.6036 1.3182 75.6166
SNU-C4 CTRP1 1.4237 2.7724 1.4235 74.1055
LoVo CTRP1 1.4634 3.2176 1.461 72.9124
HCT 116 CTRP1 1.4641 2.5576 1.464 73.8167
RKO CTRP1 1.5283 2.4719 1.5283 73.0035
KM12 CTRP1 1.6581 2.7396 1.6581 71.109
HT115 CTRP1 1.6683 2.6008 1.6683 71.0285
SNU-61 CTRP1 1.6702 2.9618 1.6699 70.7917
NCI-H508 CTRP1 1.7472 3.2021 1.7464 69.5719
SW948 CTRP1 1.787 2.8169 1.7869 69.3158
LS123 CTRP1 1.9182 3.473 1.9164 67.1243
HT-29 CTRP1 2.1269 3.7273 2.1239 64.2114
COLO 678 CTRP1 2.2466 3.65 2.2452 62.6744
HT-55 CTRP1 2.3492 3.2731 2.3491 61.3434
HCT 8 CTRP1 2.3746 3.362 2.3745 60.9754
CL-34 CTRP1 2.8541 4.2897 2.8502 54.0993
SNU-1040 CTRP1 2.8597 3.7443 2.8596 54.0583
CL-40 CTRP1 2.9497 4.1316 2.9486 52.7657
MDST8 CTRP1 2.9848 3.5083 2.9848 52.2724
RCM-1 [Human ESC] CTRP1 3.0746 3.7105 3.0746 50.9898
COLO 320 CTRP1 3.9821 14.5308 0.3098 45.828
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hep-G2 CTRP1 2.0478 3.2355 2.0476 65.5696
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2342 CTRP1 0.6364 1.754 0.6364 84.8562
NCI-H1836 CTRP1 0.9009 1.9279 0.9009 81.6034
NCI-H596 CTRP1 0.968 2.2013 0.968 80.3602
HCC15 CTRP1 1.0745 2.4108 1.0743 78.7743
HCC1833 CTRP1 1.2545 5.3831 1.0523 68.9792
NCI-H1105 CTRP1 1.2711 2.2094 1.2711 76.6208
T3M-10 CTRP1 1.3479 2.9211 1.347 74.7576
NCI-H2081 CTRP1 1.3906 2.7737 1.3903 74.5056
NCI-H1876 CTRP1 1.4579 2.6312 1.4579 73.8343
NCI-H841 CTRP1 1.5282 2.9777 1.5277 72.5581
CAL-12T CTRP1 1.6625 2.9522 1.6622 70.8998
HCC1359 CTRP1 1.6721 3.2127 1.6709 70.4937
HCC2935 CTRP1 1.8964 3.3545 1.8953 67.516
COLO 699 CTRP1 1.9101 2.7789 1.9101 67.6072
NCI-H2073 CTRP1 1.9976 3.1819 1.9974 66.2795
HCC2108 CTRP1 2.0047 3.2044 2.0045 66.1724
NCI-H1781 CTRP1 2.0661 2.8801 2.0661 65.3897
NCI-H1694 CTRP1 2.0944 2.8945 2.0944 64.9857
NCI-H441 CTRP1 2.1166 3.6155 2.1148 64.4322
NCI-H2122 CTRP1 2.1704 3.0905 2.1704 63.8925
NCI-H2172 CTRP1 2.3229 4.1932 2.3123 61.2926
NCI-H3255 CTRP1 2.3322 3.3664 2.3321 61.5746
COR-L23 CTRP1 2.3625 3.4244 2.3624 61.1386
HCC4006 CTRP1 2.3718 3.6604 2.371 60.956
NCI-H2023 CTRP1 2.4519 3.4268 2.4518 59.8749
NCI-H1755 CTRP1 2.642 3.7974 2.6415 57.1478
SK-LU-1 CTRP1 2.8504 4.0802 2.8491 54.1762
NCI-H2030 CTRP1 2.874 4.0113 2.8732 53.8467
HCC1195 CTRP1 3.0081 3.5151 3.0081 51.939
NCI-H460 CTRP1 3.0104 3.4612 3.0104 51.9067
Sq-1 CTRP1 3.1508 4.2133 3.1501 49.9009
HCC827 CTRP1 3.4156 4.1944 3.4156 46.1181
NCI-H2110 CTRP1 7.9333 15.421 3.2781 21.3025
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COV434 CTRP1 -0.1352 1.0496 -0.1352 92.922
OVK18 CTRP1 0.6701 2.3043 0.6697 82.9582
COV644 CTRP1 1.4453 2.5309 1.4453 74.0833
RMG-I CTRP1 1.576 2.6669 1.576 72.2546
OV-90 CTRP1 1.7471 3.4953 1.7437 69.1977
TYK-nu CTRP1 1.7974 3.0429 1.7972 69.057
COV362 CTRP1 1.8051 3.206 1.8045 68.8278
SNU-840 CTRP1 2.3342 3.9939 2.3292 61.3001
RMUG-S CTRP1 2.6839 4.2373 2.6787 56.4726
JHOM-1 CTRP1 2.8106 3.8857 2.8102 54.7531
Caov-3 CTRP1 2.8162 3.7914 2.8161 54.6767
OV7 CTRP1 2.9284 3.7891 2.9284 53.077
JHOC-5 CTRP1 3.1356 3.6336 3.1356 50.1183
EFO-27 CTRP1 3.4058 4.9494 3.392 46.3099
OAW42 CTRP1 3.412 3.9303 3.412 46.1699
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-MEL-1 CTRP1 1.4501 2.6756 1.45 73.8916
SK-MEL-5 CTRP1 1.6567 2.4691 1.6567 71.223
A-375 CTRP1 1.749 2.4954 1.749 69.917
SK-MEL-28 CTRP1 3.0946 3.3979 3.0946 50.7039
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1080 CTRP1 2.5591 3.409 2.5591 58.3511

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
3 Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner. Acta Pharm Sin B. 2022 Mar;12(3):1271-1287. doi: 10.1016/j.apsb.2021.09.007. Epub 2021 Sep 11.